The worst half-year period for a decade leaves the biggest medical device companies half a trillion dollars poorer.
A look for winners and losers finds a sector laid low by poor sentiment and Covid fatigue, with Lantheus, Vertex and Jazz providing a few bright spots.
Spending heavily on buybacks and dividends does not mean sector-leading share price performance, Evaluate Vantage finds.
Amid a difficult start to the year for the drug development sector, Abbvie, Bayer, Ipsen and Lantheus stand out as stock market gainers.
A look at stock performances over the first quarter of 2022 shows the extent to which investors have backed away from high-risk drug development.
This month has seen two blank-cheque company deals fall apart, and more terminations should be expected.
Lilly pips Pfizer to the big pharma top spot on share price performance, while Covid-19 drives the largest risers elsewhere.